Erste Asset Management GmbH Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD

Erste Asset Management GmbH cut its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 25.8% during the third quarter, Holdings Channel.com reports. The firm owned 133,700 shares of the biopharmaceutical company’s stock after selling 46,600 shares during the period. Erste Asset Management GmbH’s holdings in ACADIA Pharmaceuticals were worth $2,850,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ACAD. Norges Bank purchased a new stake in ACADIA Pharmaceuticals during the second quarter worth $31,679,000. TFG Asset Management GP Ltd increased its holdings in shares of ACADIA Pharmaceuticals by 50.8% in the 2nd quarter. TFG Asset Management GP Ltd now owns 161,396 shares of the biopharmaceutical company’s stock valued at $3,481,000 after acquiring an additional 54,396 shares during the period. First Trust Advisors LP raised its position in shares of ACADIA Pharmaceuticals by 2.8% in the 2nd quarter. First Trust Advisors LP now owns 2,434,376 shares of the biopharmaceutical company’s stock worth $52,509,000 after acquiring an additional 65,914 shares in the last quarter. GSA Capital Partners LLP raised its position in shares of ACADIA Pharmaceuticals by 210.1% in the 3rd quarter. GSA Capital Partners LLP now owns 75,902 shares of the biopharmaceutical company’s stock worth $1,620,000 after acquiring an additional 51,428 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of ACADIA Pharmaceuticals by 613.4% during the 3rd quarter. SG Americas Securities LLC now owns 39,680 shares of the biopharmaceutical company’s stock worth $847,000 after purchasing an additional 34,118 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the transaction, the executive vice president directly owned 7,609 shares of the company’s stock, valued at approximately $177,898.42. This represents a 47.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 26.50% of the company’s stock.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 beat and upgraded 2026 revenue outlook — ACAD reported stronger-than-expected Q4 results (EPS beat) and a milestone year with >$1B in revenue, and guided 2026 revenue to $1.22B–$1.28B, driven by NUPLAZID and DAYBUE. This underpins growth expectations for the company. Acadia Reports Q4 & Full Year 2025 Results
• Positive Sentiment: Analyst price-target upgrades — Several firms raised targets after the quarter (TD Cowen to $37 and Citizens JMP to $35), reflecting confidence in commercial momentum for DAYBUE and NUPLAZID. Benzinga coverage of analyst moves
• Neutral Sentiment: Minor analyst downtick but still constructive — Royal Bank of Canada trimmed its target to $30 but keeps an “outperform” view; this is a modest adjustment rather than a directional reversal. Benzinga: RBC target change
• Neutral Sentiment: Short-interest data appears anomalous — February short-interest entries show 0 shares / NaN increases and 0.0 days-to-cover, indicating a data/reporting glitch rather than a real shift in short positioning.
• Negative Sentiment: Analyst EPS cuts from HC Wainwright — HC Wainwright trimmed Q3 and Q4 2026 EPS estimates (Q3: $0.16 from $0.24; Q4: $0.23 from $0.27), which can pressure near-term expectations despite a buy rating and $37 target.
• Negative Sentiment: Some sell-side caution — Stifel lowered its target to $24 and moved to a “hold,” a more conservative stance that adds selling pressure versus the upgrades. Benzinga: Stifel target change
• Negative Sentiment: Pipeline/regulatory and sales nuances — Coverage noted a sales miss in places and an EU setback for trofinetide that clouds parts of the growth narrative even as core brands accelerate. Zacks: Q4 recap and trofinetide outlook

ACADIA Pharmaceuticals Trading Down 0.3%

NASDAQ:ACAD opened at $24.56 on Friday. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.40 and a 12 month high of $28.35. The firm has a fifty day simple moving average of $25.53 and a 200-day simple moving average of $24.44. The company has a market capitalization of $4.16 billion, a P/E ratio of 10.72, a PEG ratio of 8.69 and a beta of 0.66.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $1.48. The firm had revenue of $298.00 million for the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 13.96% and a net margin of 36.49%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.86 EPS. Equities analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. cut their target price on ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Monday, November 17th. Weiss Ratings restated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Citigroup increased their target price on shares of ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Wolfe Research assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $33.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.74.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.